Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | MT-5111 |
Synonyms | |
Therapy Description |
MT-5111 is an Erbb2 (Her2) antibody in conjugation with a ribosome-targeting toxin, which may demonstrate cytotoxicity against Erbb2 (Her2)-positive tumor cells (Cancer Res 2018;78(13 Suppl):Abstract nr 5769). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
MT-5111 | MT5111|MT 5111 | HER2 (ERBB2) Antibody 76 | MT-5111 is an Erbb2 (Her2) antibody in conjugation with a ribosome-targeting toxin, which may demonstrate cytotoxicity against Erbb2 (Her2)-positive tumor cells (Cancer Res 2018;78(13 Suppl):Abstract nr 5769). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04029922 | Phase I | MT-5111 | Study of MT-5111 in HER2-positive Solid Tumors (MT-5111) | Terminated | USA | NZL | AUS | 0 |